Evofem Biosciences to Participate in Stifel 2021 Virtual Healthcare Conference
PR Newswire
SAN DIEGO
,
Nov. 4, 2021
/PRNewswire/ — Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer
Saundra Pelletier
will participate in the Stifel 2021 Virtual Healthcare Conference as follows:
|
|
|
|
|
|
|
|
|
The webcast will be archived in the Events and Presentations section of the Company’s website at
https://evofem.investorroom.com/Stifel2021
.
Additionally, Evofem Biosciences will host one-on-one meetings on
Tuesday, November 16, 2021
. Meetings can be requested exclusively via Stifel.
About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company’s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at
phexxi.com
and
evofem.com
.
Phexxi
®
is a registered trademark of Evofem Biosciences, Inc.
Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
[email protected]
Mobile: (917) 673-5775
View original content to download multimedia:
https://www.prnewswire.com/news-releases/evofem-biosciences-to-participate-in-stifel-2021-virtual-healthcare-conference-301416407.html
SOURCE Evofem Biosciences, Inc.